Refine Results
Sort By
From
To
Page 2
Page 2
Communicating Science : A Practical Guide
Each of the main parts is subdivided into two sections, Guidelines and Genres, with entries arranged in alphabetical order. The guidelines are devoted to entries such as acronyms, active or passive voice, body language, figures and captions, introduction, irony, and taking the floor. Within genres, all possible media of communicating science are treated, e.g. the after-dinner speech, conference presentation, keynote lecture, magazine article, research proposal, and teleconference.
Brilliant light in life and material sciences
This book aim to create a synchrotron radiation facility, CANDLE, as an international laboratory for advanced research in life and material sciences. About 50 researchers from NATO, partner countries and Armenia gathered at Yerevan to discuss modern trends in developments of advanced light sources with high spectral brilliance and applications in basic and applied research in a wide range of fields. Research with high brilliant photon beams are used, for example for practical applications in pharmacy, electronics and nanotechnology. Such practical relevance promoted the design and construction of now more than 50 such facilities worldwide. Overview and specialized talks on the status and highlights of newly constructed light sources (ALBA, SPEAR3, European XFEL Facility, Siberian Synchrotron Radiation Center, CANDLE), on instrumentation and development of experimental techniques, and frontier research in life and material sciences using synchrotron radiation have been presented.
Alzheimers Disease
Alzheimer’s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors).
